The seasonal malaria chemoprevention (SMC) represents one of the key interventions for malaria elimination in seasonal malaria transmission settings. However, though the SMC was implemented in Burkina Faso since the last ten years, the incidence of malaria in children of 3 to 59 months under seasonal malaria chemoprevention (SMC) remains high in the country. To enhance the intervention's effectiveness in its routine system, strategies are being explored, including a new delivery approach in which community health workers directly supervise the administration of the three doses of SMC therapy (3DOT), compared to the standard delivery approach in which only the first dose is directly observed therapy (1DOT) and the remaining two doses are given to the child's guardians or parents, who must administer them to the child over the following two days. While the search for the most effective delivery strategy for SMC continues, our study aimed to identify factors associated with malaria under the 3DOT and 1DOT delivery of SMC in children aged 3 to 59 months in 2 districts in Burkina Faso. We identified factors associated with malaria in 2440 children included in a quasi-experimental cluster randomized trial, before-after with a control group design. Four health and social promotion centers were randomly selected in the Boromo health district (1DOT) and 3 in the Gaoua health district (3DOT) to receive a monthly four rounds of SMC with Sulfadoxine-pyrimethamine plus Amodiaquine. A survey logistic regression calculated the odds ratios of association between variables and malaria with significance threshold ɑ= 0.05. The results revealed, lack of optimal supervision (aOR = 2.466 [1.650–3.686], p < 0.0001), lack of optimal coverage (aOR = 4.881 [2.454–9.708], p < 0.0001), total vomiting/rejection (aOR = 14.016 [2.169–90.552], p = 0.0055), residence in the health district of Gaoua (3DOT) (aOR = 2.057 [1.425–2.970], p = 0.0001) and past history of fever (aOR = 3.045 [1.630–5.686], p = 0.0005) were significantly associated with malaria in children under five years of age under SMC. The factors associated with malaria under SMC identified in this study support the conclusion of the superiority of 3DOT compared to 1DOT to reduce the prevalence of malaria. Addressing these factors would make the strategy more relevant for the elimination of malaria by 2030.
Published in | Central African Journal of Public Health (Volume 11, Issue 4) |
DOI | 10.11648/j.cajph.20251104.12 |
Page(s) | 165-178 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
SMC, Factors Associated, Malaria, 3DOT, Burkina Faso
Assumption | Expected relative reduction | Incidence rate 1DOT (case in person-months) | Incidence rate 3DOT (case in person-months) | m (Cluster size) | K (the coefficient of variation of | Assumption | Expected relative reduction |
---|---|---|---|---|---|---|---|
1 | 75% | 0,24 | 0,06 | 300 | 0,39 | 4 | 1200 |
2 | 67% | 0,24 | 0,0792 | 300 | 0,39 | 6 | 1800 |
3 | 50% | 0,24 | 0,12 | 300 | 0,39 | 12 | 3600 |
4 | 34% | 0,24 | 0,1584 | 300 | 0,39 | 30 | 9000 |
5 | 30% | 0,24 | 0,168 | 300 | 0,39 | 36 | 10800 |
Features | 1DOT | 3DOT | P | ||
---|---|---|---|---|---|
(n) | (%) | (n) | (%) | ||
Age | 0.0004 | ||||
[3 months -1 year] | 307 | 23.35 | 140 | 16.51 | |
[1year - 2 years [ | 200 | 15.21 | 127 | 14.98 | |
[2years – 5 years [ | 808 | 61.44 | 581 | 68.51 | |
Sex | 0.7688 | ||||
Male | 767 | 50.73 | 466 | 51.38 | |
Female | 745 | 49.27 | 441 | 48.62 | |
Possession of a bed net | <0.0001 | ||||
Yes | 1329 | 87.66 | 719 | 77.81 | |
No | 187 | 12.34 | 205 | 22.19 | |
Sleep under a LLIN last night | <0.0001 | ||||
Yes | 1316 | 89.04 | 584 | 65.40 | |
No | 162 | 10.96 | 309 | 34.60 | |
Past history of fever | 0.0005 | ||||
Yes | 50 | 3.30 | 59 | 6.39 | |
No | 1466 | 96.70 | 865 | 93.61 | |
Children under 5 years of age with a tutor | <0.0001 | ||||
1 child | 349 | 30.56 | 306 | 36.17 | |
[2-6[ | 750 | 65.67 | 538 | 63.59 | |
≥6 | 43 | 3.77 | 2 | 0.24 | |
Number of persons in the family | <0.0001 | ||||
[0-6[ | 676 | 60.52 | 309 | 36.40 | |
[6-11[ | 280 | 25.07 | 317 | 37.34 | |
[11-21[ | 123 | 11.01 | 188 | 22.14 | |
>21 | 38 | 3.40 | 35 | 4.12 | |
Distance from CHSP | <0.0001 | ||||
< 5km | 944 | 97.42 | 100 | 28.90 | |
≥5km | 25 | 2.58 | 246 | 71.10 | |
Tutors | 0.0002 | ||||
Legal Guardian | 332 | 22.68 | 270 | 30.13 | |
Mother | 981 | 67.01 | 531 | 59.26 | |
Father | 151 | 10.31 | 95 | 10.60 | |
Level of education of parent/guardian | 0.9354 | ||||
Not schooled | 1019 | 91.14 | 731 | 91.03 | |
Schooled | 99 | 8.86 | 72 | 8.97 | |
Gender of parent/guardian | |||||
Male | 151 | 10.31 | 95 | 10.60 | |
Female | 1313 | 89.69 | 801 | 89.40 | |
Marital status | <.0001 | ||||
Single | 48 | 3.23 | 97 | 10.60 | |
In a couple | 1437 | 96.77 | 818 | 89.40 | |
Age of parent/guardian | <0.0001 | ||||
<18 years | 5 | 0.40 | 31 | 3.63 | |
[18-25[ | 264 | 21.17 | 136 | 15.94 | |
[25-60[ | 961 | 77.06 | 636 | 74.56 | |
[60-79[ | 17 | 1.36 | 50 | 5.86 |
Features | n+/N | OR;95%IC | P |
---|---|---|---|
Age | 0.7695 | ||
[3 months -1 year] | 58/438 | 1 | |
[1year - 2 years [ | 48/318 | 1.165 [0.771 1.760] | |
[2years – 5 years [ | 190/1350 | 1.073 [0.782 1.472] | |
Sex | 0.5497 | ||
Male | 166/1160 | 1 | |
Female | 160/1189 | 0.931 [0.737 1.177] | |
Health district | <0.0001 | ||
1DOT | 171/1461 | 1 | |
3DOT | 155/887 | 1.605 [1.268 2.031] | |
Possession of a bed net | 0.4341 | ||
Oui | 272/1998 | 1 | |
Non | 54/356 | 1.135 [0.827 1.557] | |
Past history of fever | 0.0071 | ||
No | 302/2249 | 1 | |
Yes | 24/105 | 1.910 [1.192 3.061] | |
Distance from CHSP | <0.0001 | ||
< 5km | 109/1013 | 1 | |
≥5 km | 56/259 | 2.288 [1.602 3.268] | |
Sleep under a LLIN last night | 0.3425 | ||
Yes | 239/1779 | 1 | |
No | 86/573 | 1.138 [0.872 1.486] | |
Children below 5 years of age with a tutor | 0.0330 | ||
1 | 98/636 | 1 | |
≥2 | 155/1300 | 0.743 [0.566 0.976] | |
Persons in the family | 0.3945 | ||
[0-6[ | 123/960 | 1 | |
[6-11[ | 81/584 | 1.096 [0.811 1.481] | |
≥11 | 122/810 | 1.207 [0.921 1.581] | |
Parent/guardian | 0.0555 | ||
Legal Guardian | 190/1469 | 1 | |
Mother | 96/579 | 1.338 [1.025 1.747] | |
Father | 28/244 | 0.873 [0.572 1.331] | |
Level of education of parent/guardian | 0.1493 | ||
Schooled | 28/169 | 1 | |
Not schooled | 215/1700 | 0.729 [0.474 1.120] | |
Gender of parent/guardian | 0.2861 | ||
Male | 28/244 | 1 | |
Female | 286/2048 | 1.252 [0.828 1.892] | |
Marital status | 0.5577 | ||
In a couple | 302/2183 | 1 | |
Single | 16/133 | 0.852 [0.498 1.456] | |
Age of tutors | 0.8440 | ||
< 25ans | 59/425 | 1 | |
≥ 25 ans | 230/1613 | 0.970 [0.712 1.320] | 0.8440 |
Features | n+/N | OR;95%IC | P |
---|---|---|---|
knowledge of malaria prevention | 0.1213 | ||
Yes | 231/1750 | 1 | |
No | 95/604 | 1.227 [0.947 1.590] | 0.1213 |
knowledge of malaria symptoms | 0.0003 | ||
Yes | 258/1994 | 1 | |
No | 45/202 | 1.929 [1.351 2.754] | 0.0003 |
Optimal coverage | <0.0001 | ||
Yes | 243/2033 | 1 | |
No | 67/211 | 3.428 [2.491 4.717] | <0.0001 |
Optimal supervision | 0.0004 | ||
Yes | 66/739 | 1 | |
No | 199/1396 | 1.695 [1.263 2.275] | 0.0004 |
Total rejection/vomiting | <0.0001 | ||
No | 259/2100 | 1 | |
Yes | 7/10 | 16.585 [4.262 64.536] | <0.0001 |
Features | aOR; 95%CI | P |
---|---|---|
Health district | 0.0001 | |
1DOT | 1 | |
3DOT | 2.057 [1.425 2.970] | |
Past history of fever | 0.0005 | |
Yes | 1 | |
No | 3.045 [1.630 5.686] | |
Distance from CHSP | 0.0641 | |
< 5km | 1 | |
≥ km | .492 [0.948 6.552] | |
Age | 0.7020 | |
[3 months -1 year] | 1 | |
[1year - 2 years [ | 1.471 [0.599 3.613] | |
[2years – 5 years [ | 1.223 [0.590 2.534] | |
Sleep under a LLIN last night | 0.0256 | |
Yes | 1 | |
No | 1.459 [0.232 1.909] | |
Children below 5 years of age with a tutor | 0.1291 | |
1 | 1 | |
≥2 | 1.504 [0.888 2.547] | |
Tutors | 0.8279 | |
Legal Guardian | 1 | |
Mother | 0.912 [0.484 1.719] | |
Father | 0.853 [0.499 1.456] | |
Level of education of tutors | 0.3715 | |
Schooled | 1 | |
Not schooled | 0.777 [0.446 1.352] | |
knowledge of malaria prevention | 0.1125 | |
Yes | 1 | |
No | 0.611 [0.333 1.123] | |
knowledge of malaria symptoms | 0.0658 | |
Yes | 1 | |
No | 1.149 [0.819 3.785] | |
Optimal coverage | <0.0001 | |
Yes | 1 | |
No | 4.881 [2.454 9.708] | |
Optimal supervision | <0.0001 | |
Yes | 1 | |
No | 2.466 [1.650 3.686] | |
Total rejection/vomiting | 0.0055 | |
No | 1 | |
Yes | 14.016 [2.169 90.552] |
CHSP | Center of Health and Social Promotion |
OR | Odds Ratio |
1DOT | One Directly Observed Therapy |
3DOT | Three Directly Observed Therapy |
CHWs | Community Health Workers |
CI | Confidence Interval |
iCCM | Integrated Community Case Management in the Child |
LLINs | Long-lasting Insecticide-treated Nets |
RDT | Rapid Diagnostic Tests |
SMC | Seasonal Malaria Chemoprevention |
SP-AQ | Sulfadoxine-pyrimethamine Plus Amodiaquine |
WHO | World Health Organization |
[1] | World Health Organization. Seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in children: a field guide. Published online 2013: 56. |
[2] | Cairns M, Ceesay SJ, Sagara I, et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case-control studies in 5 countries. PLoS Med. 2021; 18(9): e1003727. |
[3] | Kirakoya-Samadoulougou F, De Brouwere V, Fokam AF, Ouédraogo M, Yé Y. Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. Malar J. 2022; 21(1): 143. |
[4] | Somé AF, Zongo I, Sagara I, et al. Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger. Trop Med Infect Dis. 2022; 7(9): 214. |
[5] | Diawara SI, Konaté D, Kayentao K, et al. Effect of seasonal malaria chemoprevention in children between 5 and 9 years old in Kita and Bafoulabe districts, Mali. Parasite Epidemiol Control. 2022; 18: e00258. |
[6] |
Institut National de la Statistique et de la Démographie (INSD) and ICF International. Enquête démographique et de santé du Burkina Faso 2021.
https://dhsprogram.com/pubs/pdf/PR139/PR139.pdf 2022. Accessed May 12, 2025. |
[7] |
Ministère de la santé. Annuaire statistique 2023.
http://cns.bf/IMG/pdf/annuaire_2023_mshp_signe_020824.pdf 2024. Accessed May 12, 2025. |
[8] | Konaté AT, Yaro JB, Ouédraogo AZ, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011; 8(2): e1000408. |
[9] | Tiono AB, Kangoye DT, Rehman AM, et al. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS One. 2014; 9(1): e86936. |
[10] | de Kock M, Tarning J, Workman L, et al. Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. Antimicrob Agents Chemother. 2018; 62(5): e01370-17. |
[11] | Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010; 66(10): 1025-1035. |
[12] | Cairns ME, Sagara I, Zongo I, et al. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLoS Med. 2020; 17(8): e1003214. |
[13] | Beshir KB, Muwanguzi J, Nader J, et al. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases. 2023; 23(3): 361-370. |
[14] | Roh ME, Zongo I, Haro A, et al. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. J Infect Dis. 2023; 228(7): 926-935. |
[15] | Naidoo I, Roper C. Mapping “partially resistant”, “fully resistant”, and “super resistant” malaria. Trends Parasitol. 2013; 29(10): 505-515. |
[16] | Chauvin P, Menard S, Iriart X, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in pregnant women in Yaoundé, Cameroon: emergence of highly resistant pfdhfr/pfdhps alleles. J Antimicrob Chemother. 2015; 70(9): 2566-2571. |
[17] | Mahamar A, Sumner KM, Levitt B, et al. Effect of three years’ seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. Malaria Journal. 2022; 21(1): 39. |
[18] | Moukénet A, Moudiné K, Ngarasta N, Hinzoumbe CK, Seck I. Malaria infection and predictor factors among Chadian nomads’ children. BMC Public Health. 2024; 24(1): 918. |
[19] | Alhassane Z, Yanogo PK, Kabore J, Ibrahim L, Meda N. Facteurs associés au paludisme chez les cas suspects de paludisme dans les cinq districts sanitaires de Niamey, Niger, 2019. Science et Technique, Sciences de la Santé. 2021; 44(1): 39-50. Accessed January 19, 2023. |
[20] | Yanogo PK, Yanogo C, Tinto H. Factors associated with malaria among 3 to 59 months old children in Boromo and Gaoua Health Districts, Burkina, 2020 [Research]. JIEPH. May 3, 2025. Accessed May 25, 2025. |
[21] | Yanogo PK, Yanogo C, Tinto H. Prevalence of Malaria among Children between 3 and 59 Months Old in Two Healthcare Districts of Burkina Faso, 2020. TIJPH. 2024; 12(04). |
[22] | Ministère de la santé Burkina. Plan Stratégique National 2016-2020. Published online 2016. |
[23] | Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. International Journal of Epidemiology. 1999; 28(2): 319-326. |
[24] | Ali IM, Manga IA, Nji AM, et al. Asymptomatic Plasmodium falciparum infections and determinants of carriage in a seasonal malaria chemoprevention setting in Northern Cameroon and south Senegal (Kedougou). Malar J. 2024; 23(1): 386. |
[25] | Sondo P, Tahita MC, Ilboudo H, et al. Boosting the impact of seasonal malaria chemoprevention (SMC) through simultaneous screening and treatment of household members of children receiving SMC in Burkina Faso: a protocol for a randomized open label trial. Arch Public Health. 2022; 80(1): 41. |
[26] | Xu M, Hu YX, Lu SN, et al. Seasonal malaria chemoprevention in Africa and China’s upgraded role as a contributor: a scoping review. Infect Dis Poverty. 2023; 12(1): 63. |
[27] | Gao C, Huang S, Ibinaiye T, et al. Examination of factors impacting spitting or vomiting among children under 5 years of age during seasonal malaria chemoprevention: a quantitative study in Burkina Faso, Chad, Nigeria and Togo. Trop Med Health. 2024; 52(1): 82. |
[28] | Compaoré R, Yameogo MWE, Millogo T, Tougri H, Kouanda S. Evaluation of the implementation fidelity of the seasonal malaria chemoprevention intervention in Kaya health district, Burkina Faso. PLOS ONE. 2017; 12(11): e0187460. |
[29] | Ministère de la Santé Burkina Faso. Annuaire statistique 2014. 2015. Accessed May 25, 2025. http://cns.bf/IMG/pdf/annuaire_2014_du_ms.pdf |
[30] | Ministère de la Santé Burkina Faso. Annuaire statistique 2015. 2016. Accessed May 25, 2025. http://cns.bf/IMG/pdf/annuaire_ms_2015_signe.pdf |
[31] | Ogbulafor N, Uhomoibhi P, Shekarau E, et al. Facilitators and barriers to seasonal malaria chemoprevention (SMC) uptake in Nigeria: a qualitative approach. Malar J. 2023; 22(1): 120. |
[32] | World Health Organization. Seasonal Malaria Chemoprevention with Sulfadoxine-Pyrimethamine Plus Amodiaquine in Children: A Field Guide. 2nd ed. World Health Organization; 2023. |
[33] |
Ministère de la Santé et de l’Hygiène publique Burkina. Annuaire statistique 2020.
https://www.sante.gov.bf/fileadmin/user_upload/storages/annuaire_statistique_ms_2020_signe.pdf 2020. Accessed February 27, 2024. |
[34] | Aminou EYYM, Djedanem M, Ramatoulaye L, et al. Burden of Malaria in Adults in Sahelian Niger: A Retrospective Study (2019-2021). Am J Trop Med Hyg. Published online May 20, 2025: tpmd240613. |
[35] | Dangbenon E, Atchadé MN, Akogbéto MC, et al. Spatial and temporal variation of malaria incidence in children under 10 years in a pyrethroid-resistant vector area in southern Benin. Malar J. 2025; 24(1): 157. |
[36] | Ndiaye JLA, Ndiaye Y, Ba MS, et al. Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial. PLoS Med. 2019; 16(3): e1002762. |
[37] | Bohissou FET, Sondo P, Inoue J, et al. Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso. Sci Rep. 2024; 14: 24224. |
[38] | Millogo KS, Zabré A, Sondo P, et al. Seasonal malaria chemoprevention and mutations in Pfdhfr and Pfdhps genes in children in the health district of Nanoro, Burkina Faso. Malariaworld J. 2025; 16: 5. |
[39] | Millogo KS, Kaboré B, Sondo P, et al. Trend of N86Y and Y184F Mutations in Pfmdr1 Gene in Children Under Seasonal Malaria Chemoprevention Coverage in Nanoro, Burkina Faso. Acta Parasitol. 2024; 69(4): 1967-1976. |
[40] | Dicko A, Sagara I, Djimdé AA, et al. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J. 2010; 9: 9. |
[41] | Plowe CV. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022; 21(1): 104. |
[42] | Crutcher JM, Hoffman SL. Malaria. In: Baron S, ed. Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston; 1996. Accessed June 20, 2025. |
[43] | Temu EA, Coleman M, Abilio AP, Kleinschmidt I. High Prevalence of Malaria in Zambezia, Mozambique: The Protective Effect of IRS versus Increased Risks Due to Pig-Keeping and House Construction. PLOS ONE. 2012; 7(2): e31409. |
[44] | Mabunda S, Aponte JJ, Tiago A, Alonso P. A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings. Malar J. 2009; 8: 74. |
[45] | Smith T, Charlwood JD, Kitua AY, et al. Relationships of malaria morbidity with exposure to Plasmodium falciparum in young children in a highly endemic area. Am J Trop Med Hyg. 1998; 59(2): 252-257. |
[46] | West PA, Protopopoff N, Rowland M, et al. Malaria Risk Factors in North West Tanzania: The Effect of Spraying, Nets and Wealth. PLOS ONE. 2013; 8(6): e65787. |
APA Style
Kiswendsida, Y. P., Nadine, S. E., Chantal, Y., Smaïla, O., Nicolas, M., et al. (2025). Factors Associated with Malaria in Children Aged 3 to 59 Months Under Seasonal Malaria Chemoprevention with Direct Observation Therapy in Two Districts in Burkina Faso, 2020: A Quasi-Experimental Trial. Central African Journal of Public Health, 11(4), 165-178. https://doi.org/10.11648/j.cajph.20251104.12
ACS Style
Kiswendsida, Y. P.; Nadine, S. E.; Chantal, Y.; Smaïla, O.; Nicolas, M., et al. Factors Associated with Malaria in Children Aged 3 to 59 Months Under Seasonal Malaria Chemoprevention with Direct Observation Therapy in Two Districts in Burkina Faso, 2020: A Quasi-Experimental Trial. Cent. Afr. J. Public Health 2025, 11(4), 165-178. doi: 10.11648/j.cajph.20251104.12
AMA Style
Kiswendsida YP, Nadine SE, Chantal Y, Smaïla O, Nicolas M, et al. Factors Associated with Malaria in Children Aged 3 to 59 Months Under Seasonal Malaria Chemoprevention with Direct Observation Therapy in Two Districts in Burkina Faso, 2020: A Quasi-Experimental Trial. Cent Afr J Public Health. 2025;11(4):165-178. doi: 10.11648/j.cajph.20251104.12
@article{10.11648/j.cajph.20251104.12, author = {Yanogo Pauline Kiswendsida and Sanou Estelle Nadine and Yanogo Chantal and Ouédraogo Smaïla and Meda Nicolas and Halidou Tinto}, title = {Factors Associated with Malaria in Children Aged 3 to 59 Months Under Seasonal Malaria Chemoprevention with Direct Observation Therapy in Two Districts in Burkina Faso, 2020: A Quasi-Experimental Trial }, journal = {Central African Journal of Public Health}, volume = {11}, number = {4}, pages = {165-178}, doi = {10.11648/j.cajph.20251104.12}, url = {https://doi.org/10.11648/j.cajph.20251104.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20251104.12}, abstract = {The seasonal malaria chemoprevention (SMC) represents one of the key interventions for malaria elimination in seasonal malaria transmission settings. However, though the SMC was implemented in Burkina Faso since the last ten years, the incidence of malaria in children of 3 to 59 months under seasonal malaria chemoprevention (SMC) remains high in the country. To enhance the intervention's effectiveness in its routine system, strategies are being explored, including a new delivery approach in which community health workers directly supervise the administration of the three doses of SMC therapy (3DOT), compared to the standard delivery approach in which only the first dose is directly observed therapy (1DOT) and the remaining two doses are given to the child's guardians or parents, who must administer them to the child over the following two days. While the search for the most effective delivery strategy for SMC continues, our study aimed to identify factors associated with malaria under the 3DOT and 1DOT delivery of SMC in children aged 3 to 59 months in 2 districts in Burkina Faso. We identified factors associated with malaria in 2440 children included in a quasi-experimental cluster randomized trial, before-after with a control group design. Four health and social promotion centers were randomly selected in the Boromo health district (1DOT) and 3 in the Gaoua health district (3DOT) to receive a monthly four rounds of SMC with Sulfadoxine-pyrimethamine plus Amodiaquine. A survey logistic regression calculated the odds ratios of association between variables and malaria with significance threshold ɑ= 0.05. The results revealed, lack of optimal supervision (aOR = 2.466 [1.650–3.686], p < 0.0001), lack of optimal coverage (aOR = 4.881 [2.454–9.708], p < 0.0001), total vomiting/rejection (aOR = 14.016 [2.169–90.552], p = 0.0055), residence in the health district of Gaoua (3DOT) (aOR = 2.057 [1.425–2.970], p = 0.0001) and past history of fever (aOR = 3.045 [1.630–5.686], p = 0.0005) were significantly associated with malaria in children under five years of age under SMC. The factors associated with malaria under SMC identified in this study support the conclusion of the superiority of 3DOT compared to 1DOT to reduce the prevalence of malaria. Addressing these factors would make the strategy more relevant for the elimination of malaria by 2030.}, year = {2025} }
TY - JOUR T1 - Factors Associated with Malaria in Children Aged 3 to 59 Months Under Seasonal Malaria Chemoprevention with Direct Observation Therapy in Two Districts in Burkina Faso, 2020: A Quasi-Experimental Trial AU - Yanogo Pauline Kiswendsida AU - Sanou Estelle Nadine AU - Yanogo Chantal AU - Ouédraogo Smaïla AU - Meda Nicolas AU - Halidou Tinto Y1 - 2025/07/18 PY - 2025 N1 - https://doi.org/10.11648/j.cajph.20251104.12 DO - 10.11648/j.cajph.20251104.12 T2 - Central African Journal of Public Health JF - Central African Journal of Public Health JO - Central African Journal of Public Health SP - 165 EP - 178 PB - Science Publishing Group SN - 2575-5781 UR - https://doi.org/10.11648/j.cajph.20251104.12 AB - The seasonal malaria chemoprevention (SMC) represents one of the key interventions for malaria elimination in seasonal malaria transmission settings. However, though the SMC was implemented in Burkina Faso since the last ten years, the incidence of malaria in children of 3 to 59 months under seasonal malaria chemoprevention (SMC) remains high in the country. To enhance the intervention's effectiveness in its routine system, strategies are being explored, including a new delivery approach in which community health workers directly supervise the administration of the three doses of SMC therapy (3DOT), compared to the standard delivery approach in which only the first dose is directly observed therapy (1DOT) and the remaining two doses are given to the child's guardians or parents, who must administer them to the child over the following two days. While the search for the most effective delivery strategy for SMC continues, our study aimed to identify factors associated with malaria under the 3DOT and 1DOT delivery of SMC in children aged 3 to 59 months in 2 districts in Burkina Faso. We identified factors associated with malaria in 2440 children included in a quasi-experimental cluster randomized trial, before-after with a control group design. Four health and social promotion centers were randomly selected in the Boromo health district (1DOT) and 3 in the Gaoua health district (3DOT) to receive a monthly four rounds of SMC with Sulfadoxine-pyrimethamine plus Amodiaquine. A survey logistic regression calculated the odds ratios of association between variables and malaria with significance threshold ɑ= 0.05. The results revealed, lack of optimal supervision (aOR = 2.466 [1.650–3.686], p < 0.0001), lack of optimal coverage (aOR = 4.881 [2.454–9.708], p < 0.0001), total vomiting/rejection (aOR = 14.016 [2.169–90.552], p = 0.0055), residence in the health district of Gaoua (3DOT) (aOR = 2.057 [1.425–2.970], p = 0.0001) and past history of fever (aOR = 3.045 [1.630–5.686], p = 0.0005) were significantly associated with malaria in children under five years of age under SMC. The factors associated with malaria under SMC identified in this study support the conclusion of the superiority of 3DOT compared to 1DOT to reduce the prevalence of malaria. Addressing these factors would make the strategy more relevant for the elimination of malaria by 2030. VL - 11 IS - 4 ER -